CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | methoxyflavone |
|
Accession: | CHEBI:25241
|
browse the term
|
Definition: | Any member of the class of flavones with at least one methoxy substituent. |
Synonyms: | related_synonym: | methoxyflavones |
|
|
|
G |
Ccnb1 |
cyclin B1 |
affects phosphorylation increases expression |
ISO |
5,7,3'-trihydroxy-3,4'-dimethoxyflavone affects the phosphorylation of CCNB1 protein 5,7,3'-trihydroxy-3,4'-dimethoxyflavone results in increased expression of CCNB1 protein |
CTD |
PMID:21229608 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdc25c |
cell division cycle 25C |
affects phosphorylation |
ISO |
5,7,3'-trihydroxy-3,4'-dimethoxyflavone affects the phosphorylation of CDC25C protein |
CTD |
PMID:21229608 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
affects phosphorylation |
ISO |
5,7,3'-trihydroxy-3,4'-dimethoxyflavone affects the phosphorylation of CDK1 protein |
CTD |
PMID:21229608 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
5,7,3'-trihydroxy-3,4'-dimethoxyflavone results in increased expression of CDKN1A protein |
CTD |
PMID:21229608 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Foxm1 |
forkhead box M1 |
affects phosphorylation |
ISO |
5,7,3'-trihydroxy-3,4'-dimethoxyflavone affects the phosphorylation of FOXM1 protein |
CTD |
PMID:21229608 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
increases activity |
ISO |
5,7,3'-trihydroxy-3,4'-dimethoxyflavone results in increased activity of SMPD1 protein |
CTD |
PMID:21229608 |
|
NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
|
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
tricin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] |
CTD |
PMID:16552572 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
3',5'-dimethoxyflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein] |
CTD |
PMID:12644593 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
chrysoeriol results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene binds to AHR protein] |
CTD |
PMID:20553787 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BGLAP protein] |
CTD |
PMID:20981859 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:20553787 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein] |
CTD |
PMID:20981859 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mtnr1a |
melatonin receptor 1A |
affects binding |
ISO |
chrysoeriol binds to MTNR1A protein |
CTD |
PMID:20399199 |
|
NCBI chr16:47,144,461...47,163,919
Ensembl chr16:47,144,461...47,163,919
|
|
G |
Mtnr1b |
melatonin receptor 1B |
affects binding |
ISO |
chrysoeriol binds to MTNR1B protein |
CTD |
PMID:20399199 |
|
NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:12,638,219...12,652,737
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of 1-benzyl-1,4-dihydronicotinamide] which results in increased reduction of Vitamin K 3]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3] |
CTD |
PMID:20399199 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
chrysoeriol inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFSF11 protein] |
CTD |
PMID:20981859 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein] |
CTD |
PMID:24161485 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein] |
CTD |
PMID:24161485 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein] |
CTD |
PMID:24161485 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein] |
CTD |
PMID:24161485 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:24161485 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]] which results in decreased abundance of Nitric Oxide |
CTD |
PMID:24161485 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone |
CTD |
PMID:24161485 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] |
CTD |
PMID:24161485 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of STAT1 protein]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:24161485 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of STAT3 protein]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:24161485 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; 5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein] |
CTD |
PMID:24161485 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
acacetin results in decreased expression of CCNB1 protein |
CTD |
PMID:36740148 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
acacetin results in decreased expression of CCNE1 protein |
CTD |
PMID:36740148 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
acacetin results in decreased expression of CDC25C protein |
CTD |
PMID:36740148 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
acacetin results in decreased expression of CDK1 protein |
CTD |
PMID:36740148 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
acacetin results in decreased expression of CDK2 protein |
CTD |
PMID:36740148 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
acacetin results in increased expression of CDKN1A protein |
CTD |
PMID:36740148 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
acacetin results in increased expression of CHK1 protein |
CTD |
PMID:36740148 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing increases expression decreases activity |
ISO |
CYP1A1 protein results in increased metabolism of acacetin acacetin results in increased expression of CYP1A1 mRNA acacetin results in decreased activity of CYP1A1 protein |
CTD |
PMID:10781868 PMID:21053930 PMID:21482471 PMID:31621310 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO EXP |
acacetin results in decreased activity of CYP1A2 protein |
CTD |
PMID:21053930 PMID:32738202 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing increases expression decreases activity multiple interactions |
ISO |
CYP1B1 protein results in increased metabolism of acacetin acacetin results in increased expression of CYP1B1 mRNA acacetin results in decreased activity of CYP1B1 protein acacetin binds to and results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 PMID:21053930 PMID:21482471 PMID:31621310 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
acacetin results in decreased activity of CYP2B1 protein |
CTD |
PMID:32738202 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
acacetin results in decreased activity of CYP2C11 protein |
CTD |
PMID:32738202 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
EXP |
acacetin results in decreased activity of CYP2E1 protein |
CTD |
PMID:32738202 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions increases expression |
EXP ISO |
acacetin results in decreased activity of CYP3A2 protein acacetin binds to and results in decreased activity of CYP3A4 protein; acacetin inhibits the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 4-hydroxymidazolam]; acacetin promotes the reaction [[CYP3A4 protein results in increased oxidation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam] acacetin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21053930 PMID:29933105 PMID:32738202 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression |
ISO |
acacetin results in decreased expression of FADD protein |
CTD |
PMID:36740148 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [acacetin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36740148 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
acacetin results in increased phosphorylation of MAPK3 protein Acetylcysteine inhibits the reaction [acacetin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36740148 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity increases expression multiple interactions |
ISO |
acacetin results in increased activity of NR1I2 protein acacetin results in increased expression of NR1I2 mRNA acacetin results in increased activity of and results in increased expression of NR1I2 protein; sulforaphane inhibits the reaction [acacetin results in increased activity of NR1I2 protein] |
CTD |
PMID:25455453 PMID:29933105 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression |
ISO |
acacetin results in increased expression of PARP1 protein |
CTD |
PMID:36740148 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases expression |
ISO |
acacetin results in increased expression of RIPK1 protein |
CTD |
PMID:36740148 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
increases expression |
ISO |
acacetin results in increased expression of RIPK3 protein |
CTD |
PMID:36740148 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
acacetin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:31621310 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
ISO |
casticin results in increased expression of ABCC5 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Acan |
aggrecan |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; casticin inhibits the reaction [IL1B protein results in decreased expression of ACAN protein] |
CTD |
PMID:38309612 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
increases expression |
ISO |
casticin results in increased expression of ADAM10 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS4 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS4 protein] |
CTD |
PMID:38309612 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 protein] |
CTD |
PMID:38309612 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Aftph |
aftiphilin |
decreases expression |
ISO |
casticin results in decreased expression of AFTPH mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:94,871,429...94,925,625
Ensembl chr14:94,871,429...94,925,376
|
|
G |
Agap1 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 |
decreases expression |
ISO |
casticin results in decreased expression of AGAP1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 9:90,039,720...90,475,196
Ensembl chr 9:90,039,605...90,470,958
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression multiple interactions |
ISO |
casticin results in increased expression of AIFM1 protein [Fluorouracil co-treated with casticin] results in increased expression of AIFM1 protein |
CTD |
PMID:29098808 PMID:32270916 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akirin2 |
akirin 2 |
decreases expression |
ISO |
casticin results in decreased expression of AKIRIN2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression multiple interactions |
ISO EXP |
casticin results in decreased expression of AKT1 protein casticin inhibits the reaction [IL1B protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:28444820 PMID:38309612 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
decreases expression |
ISO |
casticin results in decreased expression of AKT3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
ISO |
casticin results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Alx1 |
ALX homeobox 1 |
decreases expression |
ISO |
casticin results in decreased expression of ALX1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:38,157,626...38,177,220
Ensembl chr 7:38,147,117...38,177,220
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
casticin results in increased expression of APAF1 protein |
CTD |
PMID:27862857 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Arl6ip4 |
ARF like GTPase 6 interacting protein 4 |
decreases expression |
ISO |
casticin results in decreased expression of ARL6IP4 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr12:32,479,623...32,481,768
Ensembl chr12:32,479,625...32,481,799
|
|
G |
Armc9 |
armadillo repeat containing 9 |
decreases expression |
ISO |
casticin results in decreased expression of ARMC9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 9:86,802,791...86,928,611
Ensembl chr 9:86,802,868...86,928,860
|
|
G |
Arpc5l |
actin related protein 2/3 complex, subunit 5-like |
decreases expression |
ISO |
casticin results in decreased expression of ARPC5L mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:22,758,710...22,767,520
Ensembl chr 3:22,759,876...22,767,538 Ensembl chr 9:22,759,876...22,767,538
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
casticin results in decreased expression of ASNS mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
casticin results in decreased expression of ATF5 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
casticin results in increased expression of ATF6 protein |
CTD |
PMID:27862857 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases expression |
ISO |
casticin results in decreased expression of ATM protein |
CTD |
PMID:29098808 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
increases expression |
ISO |
casticin results in increased expression of ATOX1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp6v1g1 |
ATPase H+ transporting V1 subunit G1 |
decreases expression |
ISO |
casticin results in decreased expression of ATP6V1G1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:76,961,462...76,967,642
Ensembl chr 5:76,961,499...76,969,463
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
increases expression |
ISO |
casticin results in increased expression of ATP8A1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:40,315,013...40,557,572
Ensembl chr14:40,315,049...40,554,611
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression |
ISO |
casticin results in decreased expression of ATR protein |
CTD |
PMID:29098808 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Atxn7l3b |
ataxin 7-like 3B |
decreases expression |
ISO |
casticin results in decreased expression of ATXN7L3B mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:48,322,451...48,325,975
Ensembl chr 7:48,321,755...48,328,878
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
decreases expression |
ISO |
casticin results in decreased expression of AVPR1A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Axin2 |
axin 2 |
increases expression |
ISO |
casticin results in increased expression of AXIN2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
casticin results in increased expression of BAK1 protein |
CTD |
PMID:27862857 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
casticin results in increased expression of BAMBI mRNA |
CTD |
PMID:27862857 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
decreases expression |
ISO |
casticin results in decreased expression of BASP1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:75,816,130...75,863,801
Ensembl chr 2:75,816,122...75,864,043
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
casticin results in increased expression of BAX protein casticin inhibits the reaction [IL1B protein results in increased expression of BAX protein] casticin inhibits the reaction [Fluorouracil results in increased expression of BAX protein] |
CTD |
PMID:27862857 PMID:29098808 PMID:32270916 PMID:38309612 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl11a |
BCL11 transcription factor A |
decreases expression |
ISO |
casticin results in decreased expression of BCL11A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:98,029,018...98,124,181
Ensembl chr14:98,030,461...98,124,180
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
casticin results in decreased expression of BCL2 protein casticin inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein] [Fluorouracil co-treated with casticin] results in decreased expression of BCL2 protein |
CTD |
PMID:27862857 PMID:29098808 PMID:32270916 PMID:38309612 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions increases expression |
ISO |
casticin results in decreased expression of BCL2L1 protein casticin promotes the reaction [Fluorouracil results in decreased expression of BCL2L1 protein]; Fluorouracil promotes the reaction [casticin results in decreased expression of BCL2L1 protein] casticin results in increased expression of BCL2L1 mRNA |
CTD |
PMID:27862857 PMID:29098808 PMID:32270916 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression multiple interactions decreases expression |
ISO |
casticin results in increased expression of BID protein casticin inhibits the reaction [Fluorouracil results in increased expression of BID protein] casticin results in decreased expression of BID protein |
CTD |
PMID:27862857 PMID:29098808 PMID:32270916 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
ISO |
casticin results in decreased expression of BMAL1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmi1 |
BMI1 proto-oncogene, polycomb ring finger |
multiple interactions decreases expression |
ISO |
casticin promotes the reaction [MIR148A mRNA results in decreased expression of BMI1 mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of BMI1 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of BMI1 mRNA] |
CTD |
PMID:32268151 |
|
NCBI chr17:81,332,175...81,341,625
Ensembl chr17:81,332,214...81,388,690
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
increases expression |
ISO |
casticin results in increased expression of BMP4 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bnip2 |
BCL2 interacting protein 2 |
decreases expression |
ISO |
casticin results in decreased expression of BNIP2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
increases expression |
ISO |
casticin results in increased expression of BRCA1 protein |
CTD |
PMID:29098808 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Btf3 |
basic transcription factor 3 |
decreases expression |
ISO |
casticin results in decreased expression of BTF3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:29,659,764...29,666,898
Ensembl chr 2:29,659,231...29,666,879 Ensembl chr13:29,659,231...29,666,879
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
casticin results in decreased expression of BTG1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
increases expression |
ISO |
casticin results in increased expression of CADM1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Calcoco1 |
calcium binding and coiled coil domain 1 |
decreases expression |
ISO |
casticin results in decreased expression of CALCOCO1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:133,834,705...133,849,515
Ensembl chr 7:133,834,707...133,849,422
|
|
G |
Calm1 |
calmodulin 1 |
decreases expression |
ISO |
casticin results in decreased expression of CALM1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
ISO |
casticin results in decreased expression of CAMK4 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
casticin results in increased expression of and results in increased cleavage of CAPN1 protein |
CTD |
PMID:27862857 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
casticin results in increased expression of CAPN2 protein |
CTD |
PMID:27862857 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp2 |
caspase 2 |
increases expression |
ISO |
casticin results in increased expression of CASP2 protein |
CTD |
PMID:27862857 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
casticin results in increased cleavage of and results in increased activity of CASP3 protein casticin inhibits the reaction [IL1B protein results in increased cleavage of CASP3 protein] casticin inhibits the reaction [Fluorouracil results in increased activity of CASP3 protein] casticin results in increased activity of CASP3 protein |
CTD |
PMID:27862857 PMID:29098808 PMID:32270916 PMID:38309612 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases expression |
ISO |
casticin results in increased expression of CASP4 protein |
CTD |
PMID:27862857 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp6 |
caspase 6 |
increases expression |
ISO |
casticin results in increased expression of CASP6 protein |
CTD |
PMID:27862857 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
casticin results in increased expression of CASP7 protein |
CTD |
PMID:27862857 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
casticin results in increased cleavage of and results in increased activity of CASP8 protein; casticin results in increased expression of and results in increased activity of CASP8 protein casticin inhibits the reaction [IL1B protein results in increased cleavage of CASP8 protein] |
CTD |
PMID:27862857 PMID:29098808 PMID:38309612 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
casticin results in increased cleavage of and results in increased activity of CASP9 protein casticin promotes the reaction [Fluorouracil results in increased activity of CASP9 protein] casticin results in increased activity of CASP9 protein |
CTD |
PMID:27862857 PMID:29098808 PMID:32270916 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases expression multiple interactions |
ISO |
casticin results in increased expression of CAT protein Fluorouracil inhibits the reaction [casticin results in increased expression of CAT protein] |
CTD |
PMID:32270916 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc122 |
coiled-coil domain containing 122 |
increases expression |
ISO |
casticin results in increased expression of CCDC122 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr15:52,407,717...52,470,163
Ensembl chr15:52,407,717...52,470,163
|
|
G |
Ccdc174 |
coiled-coil domain containing 174 |
decreases expression |
ISO |
casticin results in decreased expression of CCDC174 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:124,392,183...124,419,035
Ensembl chr 4:124,392,274...124,419,035
|
|
G |
Ccdc90b |
coiled-coil domain containing 90B |
decreases expression |
ISO |
casticin results in decreased expression of CCDC90B mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:146,632,756...146,646,314
Ensembl chr 1:146,633,036...146,647,338
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
casticin results in increased expression of CCN1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
casticin results in decreased expression of CCNB1 protein |
CTD |
PMID:29098808 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cct4 |
chaperonin containing TCP1 subunit 4 |
decreases expression |
ISO |
casticin results in decreased expression of CCT4 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:96,991,853...97,004,732
Ensembl chr14:96,991,859...97,005,267
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
casticin results in increased expression of CD24 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd44 |
CD44 molecule |
decreases expression multiple interactions |
ISO |
casticin results in decreased expression of CD44 mRNA; casticin results in decreased expression of CD44 protein casticin affects the reaction [MIR148A mRNA affects the expression of CD44 mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of CD44 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of CD44 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of CD44 protein] |
CTD |
PMID:32268151 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
casticin results in decreased expression of CD83 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
casticin results in decreased expression of CDC25C protein |
CTD |
PMID:29098808 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
casticin results in decreased expression of CDC42 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh17 |
cadherin 17 |
increases expression |
ISO |
casticin results in increased expression of CDH17 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
ISO |
casticin results in increased expression of CDK2 protein |
CTD |
PMID:29098808 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
casticin results in decreased expression of CDKN1A mRNA; casticin results in decreased expression of CDKN1A protein |
CTD |
PMID:27862857 PMID:29098808 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
casticin results in increased expression of CDKN1B mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
casticin results in increased expression of CDKN2A protein |
CTD |
PMID:29098808 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
casticin results in increased expression of CHEK2 protein |
CTD |
PMID:29098808 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chic2 |
cysteine-rich hydrophobic domain 2 |
decreases expression |
ISO |
casticin results in decreased expression of CHIC2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:33,157,669...33,192,015
Ensembl chr14:33,157,537...33,191,895
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
ISO |
casticin results in decreased expression of CLDN1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cnbp |
CCHC-type zinc finger, nucleic acid binding protein |
decreases expression |
ISO |
casticin results in decreased expression of CNBP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:120,302,768...120,311,694
Ensembl chr 4:120,302,771...120,311,637
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
casticin results in decreased expression of COL1A1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; casticin inhibits the reaction [IL1B protein results in decreased expression of COL2A1 protein] |
CTD |
PMID:38309612 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
casticin results in increased expression of CPE mRNA |
CTD |
PMID:28444820 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
casticin results in increased expression of CREB1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
casticin results in decreased expression of CRHBP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Crls1 |
cardiolipin synthase 1 |
decreases expression |
ISO |
casticin results in decreased expression of CRLS1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:120,119,822...120,138,674
Ensembl chr 3:120,119,852...120,138,655
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
ISO |
casticin results in increased expression of CRYAB mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
decreases expression |
ISO |
casticin results in decreased expression of CSNK1A1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
decreases expression |
ISO |
casticin results in decreased expression of CYB5R1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
casticin results in increased expression of CYCS protein |
CTD |
PMID:27862857 PMID:29098808 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases expression |
ISO |
casticin results in decreased expression of DDIT3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
decreases expression |
ISO |
casticin results in decreased expression of DDX27 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Dip2c |
disco-interacting protein 2 homolog C |
decreases expression |
ISO |
casticin results in decreased expression of DIP2C mRNA |
CTD |
PMID:28444820 |
|
NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305
|
|
G |
Dkk3 |
dickkopf WNT signaling pathway inhibitor 3 |
decreases expression |
ISO |
casticin results in decreased expression of DKK3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:166,237,969...166,281,271
Ensembl chr 1:166,238,238...166,280,590
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions decreases activity decreases expression |
ISO |
casticin affects the reaction [MIR148A mRNA affects the activity of DNMT1 protein]; casticin affects the reaction [MIR148A mRNA affects the expression of DNMT1 mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased activity of DNMT1 protein]; casticin results in decreased expression of and results in decreased activity of DNMT1 protein; DNMT1 protein inhibits the reaction [casticin results in decreased activity of DNMT1 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of BMI1 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of CD44 protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of EPCAM protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of NANOG protein]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of POU5F1 protein]; DNMT1 protein inhibits the reaction [casticin results in increased expression of MIR148A mRNA]; MIR148A mRNA affects the reaction [casticin results in decreased activity of DNMT1 protein]; MIR148A mRNA affects the reaction [casticin results in decreased expression of DNMT1 mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased activity of DNMT1 protein] |
CTD |
PMID:32268151 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
ISO |
casticin results in decreased expression of DUSP6 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
decreases expression |
ISO |
casticin results in decreased expression of DYRK1A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
casticin results in decreased expression of EGFR protein |
CTD |
PMID:28444820 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
decreases expression |
ISO |
casticin results in decreased expression of EIF2S2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
decreases expression |
ISO |
casticin results in decreased expression of EIF5 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
increases expression |
ISO |
casticin results in increased expression of ENC1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Endog |
endonuclease G |
decreases expression increases expression multiple interactions |
ISO |
casticin results in decreased expression of ENDOG protein casticin results in increased expression of ENDOG protein casticin inhibits the reaction [Fluorouracil results in increased expression of ENDOG protein] |
CTD |
PMID:29098808 PMID:32270916 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
casticin results in decreased expression of EP300 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epb41l4b |
erythrocyte membrane protein band 4.1 like 4B |
decreases expression |
ISO |
casticin results in decreased expression of EPB41L4B mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:71,691,706...71,852,583
Ensembl chr 5:71,694,331...71,851,990
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions decreases expression |
ISO |
casticin promotes the reaction [MIR148A mRNA results in decreased expression of EPCAM mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of EPCAM protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of EPCAM mRNA] |
CTD |
PMID:32268151 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
increases expression |
ISO |
casticin results in increased expression of ERBB3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Esf1 |
ESF1 nucleolar pre-rRNA processing protein homolog |
decreases expression |
ISO |
casticin results in decreased expression of ESF1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817
|
|
G |
Exosc3 |
exosome component 3 |
decreases expression |
ISO |
casticin results in decreased expression of EXOSC3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:59,573,849...59,579,065
Ensembl chr 5:59,573,886...59,579,060
|
|
G |
Ext1 |
exostosin glycosyltransferase 1 |
increases expression |
ISO |
casticin results in increased expression of EXT1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
casticin results in increased expression of FADD protein |
CTD |
PMID:27862857 PMID:29098808 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fam227a |
family with sequence similarity 227, member A |
increases expression |
ISO |
casticin results in increased expression of FAM227A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:111,174,362...111,216,513
Ensembl chr 7:111,174,362...111,216,483
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
casticin results in increased expression of FAS protein |
CTD |
PMID:27862857 PMID:29098808 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression decreases expression |
ISO |
casticin results in increased expression of FASLG protein casticin results in decreased expression of FASLG protein |
CTD |
PMID:27862857 PMID:29098808 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxo11 |
F-box protein 11 |
decreases expression |
ISO |
casticin results in decreased expression of FBXO11 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662
|
|
G |
Fbxo44 |
F-box protein 44 |
decreases expression |
ISO |
casticin results in decreased expression of FBXO44 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:158,583,363...158,592,510
Ensembl chr 5:158,583,366...158,592,363
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
decreases expression |
ISO |
casticin results in decreased expression of FEZ1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Foxo3 |
forkhead box O3 |
decreases expression |
ISO |
casticin results in decreased expression of FOXO3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp2 |
forkhead box P2 |
decreases expression |
ISO |
casticin results in decreased expression of FOXP2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases expression |
ISO |
casticin results in decreased expression of GADD45A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
decreases expression |
ISO |
casticin results in decreased expression of GLUD1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
G |
Gphn |
gephyrin |
decreases expression |
ISO |
casticin results in decreased expression of GPHN mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
decreases expression |
ISO |
casticin results in decreased expression of GPR85 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
casticin results in decreased expression of GRB2 protein |
CTD |
PMID:28444820 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Grid2 |
glutamate ionotropic receptor delta type subunit 2 |
decreases expression |
ISO |
casticin results in decreased expression of GRID2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 4:92,415,019...93,892,472
Ensembl chr 4:92,415,230...93,889,355
|
|
G |
Gtf2h2 |
general transcription factor IIH subunit 2 |
decreases expression |
ISO |
casticin results in decreased expression of GTF2H2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:31,623,752...31,652,697
Ensembl chr 2:31,624,678...31,652,592
|
|
G |
Hcn2 |
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
decreases expression |
ISO |
casticin results in decreased expression of HCN2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased expression of HIF1A protein] |
CTD |
PMID:38309612 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hoxb8 |
homeo box B8 |
decreases expression |
ISO |
casticin results in decreased expression of HOXB8 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxb9 |
homeo box B9 |
decreases expression |
ISO |
casticin results in decreased expression of HOXB9 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
decreases expression |
ISO |
casticin results in decreased expression of HSPA4 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
casticin results in increased expression of HSPA5 protein |
CTD |
PMID:27862857 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
casticin results in increased expression of HSPA8 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
ISO |
casticin results in decreased expression of HSPA9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Il12a |
interleukin 12A |
decreases expression |
ISO |
casticin results in decreased expression of IL12A mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in decreased expression of ACAN mRNA]; casticin inhibits the reaction [IL1B protein results in decreased expression of ACAN protein]; casticin inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein]; casticin inhibits the reaction [IL1B protein results in decreased expression of COL2A1 mRNA]; casticin inhibits the reaction [IL1B protein results in decreased expression of COL2A1 protein]; casticin inhibits the reaction [IL1B protein results in increased cleavage of CASP3 protein]; casticin inhibits the reaction [IL1B protein results in increased cleavage of CASP8 protein]; casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS4 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS4 protein]; casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 protein]; casticin inhibits the reaction [IL1B protein results in increased expression of BAX protein]; casticin inhibits the reaction [IL1B protein results in increased expression of HIF1A protein]; casticin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of MMP13 protein]; casticin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of MMP9 protein]; casticin inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; casticin inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; casticin inhibits the reaction [IL1B protein results in increased phosphorylation of AKT1 protein]; casticin inhibits the reaction [IL1B protein results in increased secretion of IL1B protein]; casticin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; casticin inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:38309612 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO EXP |
casticin results in decreased expression of IL6 mRNA casticin inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:27862857 PMID:38309612 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ints6 |
integrator complex subunit 6 |
decreases expression |
ISO |
casticin results in decreased expression of INTS6 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527
|
|
G |
Irak4 |
interleukin-1 receptor-associated kinase 4 |
increases expression |
ISO |
casticin results in increased expression of IRAK4 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 7:125,682,502...125,708,294
Ensembl chr 7:125,682,488...125,717,837
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
decreases expression |
ISO |
casticin results in decreased expression of IRF2BP2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases expression |
ISO |
casticin results in decreased expression of KCNH2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kctd9 |
potassium channel tetramerization domain containing 9 |
decreases expression |
ISO |
casticin results in decreased expression of KCTD9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr15:41,942,165...41,969,862
Ensembl chr15:41,942,381...41,969,862
|
|
G |
Kirrel3 |
kirre like nephrin family adhesion molecule 3 |
decreases expression |
ISO |
casticin results in decreased expression of KIRREL3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:32,865,779...33,407,555
Ensembl chr 8:32,862,776...33,405,676
|
|
G |
Klf9 |
KLF transcription factor 9 |
decreases expression |
ISO |
casticin results in decreased expression of KLF9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Krt16 |
keratin 16 |
increases expression |
ISO |
casticin results in increased expression of KRT16 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Ldhb |
lactate dehydrogenase B |
decreases expression |
ISO |
casticin results in decreased expression of LDHB mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
casticin results in decreased expression of LEF1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lhfpl6 |
LHFPL tetraspan subfamily member 6 |
increases expression |
ISO |
casticin results in increased expression of LHFPL6 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443
|
|
G |
Limch1 |
LIM and calponin homology domains 1 |
increases expression |
ISO |
casticin results in increased expression of LIMCH1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:41,112,579...41,425,001
Ensembl chr14:41,114,803...41,425,191
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
casticin results in decreased expression of LPL mRNA |
CTD |
PMID:27862857 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
increases expression |
ISO |
casticin results in increased expression of LRP5 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Ltv1 |
LTV1 ribosome biogenesis factor |
decreases expression |
ISO |
casticin results in decreased expression of LTV1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:7,565,673...7,578,398
Ensembl chr 1:7,565,669...7,578,563
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
casticin results in decreased expression of MAF mRNA |
CTD |
PMID:28444820 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Magoh |
mago homolog, exon junction complex subunit |
decreases expression |
ISO |
casticin results in decreased expression of MAGOH mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:122,639,268...122,646,650
Ensembl chr 5:122,639,308...122,646,617
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
increases expression |
ISO |
casticin results in increased expression of MAP3K7 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapre2 |
microtubule-associated protein, RP/EB family, member 2 |
increases expression |
ISO |
casticin results in increased expression of MAPRE2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr18:15,028,675...15,169,553
Ensembl chr18:15,029,041...15,168,044
|
|
G |
Mark3 |
microtubule affinity regulating kinase 3 |
decreases expression |
ISO |
casticin results in decreased expression of MARK3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:130,626,612...130,716,245
Ensembl chr 6:130,627,482...130,716,647
|
|
G |
Max |
MYC associated factor X |
decreases expression |
ISO |
casticin results in decreased expression of MAX mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:95,636,859...95,662,204
Ensembl chr 6:95,636,858...95,662,137
|
|
G |
Mbp |
myelin basic protein |
increases expression |
ISO |
casticin results in increased expression of MBP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
casticin results in decreased expression of MCL1 protein |
CTD |
PMID:27862857 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
increases expression |
ISO |
casticin results in increased expression of MDC1 protein |
CTD |
PMID:29098808 |
|
NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
|
|
G |
Mecom |
MDS1 and EVI1 complex locus |
decreases expression |
ISO |
casticin results in decreased expression of MECOM mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:112,909,353...113,464,583
Ensembl chr 2:112,909,321...113,464,590
|
|
G |
Mest |
mesoderm specific transcript |
increases expression |
ISO |
casticin results in increased expression of MEST mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:59,354,445...59,364,919
Ensembl chr 4:59,354,447...59,366,145
|
|
G |
Mettl3 |
methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit |
decreases expression |
ISO |
casticin results in decreased expression of METTL3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr15:25,002,505...25,014,097
Ensembl chr15:25,003,172...25,014,041
|
|
G |
Mir148a |
microRNA 148a |
increases expression multiple interactions |
ISO |
casticin results in increased expression of MIR148A mRNA casticin affects the reaction [MIR148A mRNA affects the activity of DNMT1 protein]; casticin affects the reaction [MIR148A mRNA affects the expression of CD44 mRNA]; casticin affects the reaction [MIR148A mRNA affects the expression of DNMT1 mRNA]; casticin affects the reaction [MIR148A mRNA results in increased expression of MIR148A mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased activity of DNMT1 protein]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of BMI1 mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of CD44 protein]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of EPCAM mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of NANOG mRNA]; casticin promotes the reaction [MIR148A mRNA results in decreased expression of POU5F1 mRNA]; DNMT1 protein inhibits the reaction [casticin results in increased expression of MIR148A mRNA]; MIR148A mRNA affects the reaction [casticin results in decreased activity of DNMT1 protein]; MIR148A mRNA affects the reaction [casticin results in decreased expression of DNMT1 mRNA]; MIR148A mRNA affects the reaction [casticin results in increased expression of MIR148A mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased activity of DNMT1 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of BMI1 mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of CD44 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of EPCAM mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of NANOG mRNA]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of POU5F1 mRNA] |
CTD |
PMID:32268151 |
|
NCBI chr 4:80,333,762...80,333,858
Ensembl chr 4:80,333,762...80,333,858
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of MMP13 protein] |
CTD |
PMID:38309612 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
casticin results in decreased expression of MMP2 mRNA casticin results in decreased expression of MMP2 protein |
CTD |
PMID:27862857 PMID:28444820 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO EXP |
casticin results in decreased expression of MMP9 protein casticin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of MMP9 protein] |
CTD |
PMID:28444820 PMID:38309612 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mplkip |
M-phase specific PLK1 interacting protein |
decreases expression |
ISO |
casticin results in decreased expression of MPLKIP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr17:47,373,624...47,376,199
Ensembl chr17:47,373,845...47,376,204
|
|
G |
Mrpl9 |
mitochondrial ribosomal protein L9 |
increases expression |
ISO |
casticin results in increased expression of MRPL9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:182,082,012...182,086,758
Ensembl chr 2:182,076,369...182,087,095
|
|
G |
Muc13 |
mucin 13, cell surface associated |
increases expression |
ISO |
casticin results in increased expression of MUC13 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr11:66,957,208...66,980,264
Ensembl chr11:66,960,595...66,984,727
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
increases expression |
ISO |
casticin results in increased expression of MYD88 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myo7a |
myosin VIIA |
increases expression |
ISO |
casticin results in increased expression of MYO7A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:152,342,611...152,414,171
Ensembl chr 1:152,344,448...152,414,157
|
|
G |
Nanog |
Nanog homeobox |
multiple interactions decreases expression |
ISO |
casticin promotes the reaction [MIR148A mRNA results in decreased expression of NANOG mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of NANOG protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of NANOG mRNA] |
CTD |
PMID:32268151 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nars1 |
asparaginyl-tRNA synthetase 1 |
decreases expression |
ISO |
casticin results in decreased expression of NARS1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr18:57,989,308...58,005,584
Ensembl chr18:57,989,308...58,005,622
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
decreases expression |
ISO |
casticin results in decreased expression of NDUFS4 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
casticin results in decreased expression of NFKB1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases expression |
ISO |
casticin results in decreased expression of NFKB2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
ISO |
casticin results in decreased expression of NFKBIA mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
ISO |
casticin results in decreased expression of NFKBIB mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nfkbid |
NFKB inhibitor delta |
decreases expression |
ISO |
casticin results in decreased expression of NFKBID mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:85,679,353...85,690,415
Ensembl chr 1:85,680,861...85,690,447
|
|
G |
Nfkbie |
NFKB inhibitor epsilon |
decreases expression |
ISO |
casticin results in decreased expression of NFKBIE mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
|
|
G |
Nfx1 |
nuclear transcription factor, X-box binding 1 |
increases expression |
ISO |
casticin results in increased expression of NFX1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:56,104,945...56,162,912
Ensembl chr 5:56,105,234...56,162,912
|
|
G |
Nkd1 |
NKD inhibitor of WNT signaling pathway 1 |
increases expression |
ISO |
casticin results in increased expression of NKD1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr19:18,476,344...18,549,380
Ensembl chr19:18,476,344...18,549,380
|
|
G |
Nme9 |
NME/NM23 family member 9 |
increases expression |
ISO |
casticin results in increased expression of NME9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:100,013,190...100,034,511
|
|
G |
Nmt1 |
N-myristoyltransferase 1 |
decreases expression |
ISO |
casticin results in decreased expression of NMT1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:87,988,826...88,025,405
Ensembl chr10:87,988,826...88,022,648
|
|
G |
Nol4l |
nucleolar protein 4-like |
decreases expression |
ISO |
casticin results in decreased expression of NOL4L mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:141,884,840...142,007,668
Ensembl chr 3:141,884,840...142,008,976
|
|
G |
Nop58 |
NOP58 ribonucleoprotein |
decreases expression |
ISO |
casticin results in decreased expression of NOP58 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 9:61,120,939...61,144,810
Ensembl chr 9:61,120,929...61,144,810
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:38309612 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas3 |
neuronal PAS domain protein 3 |
decreases expression |
ISO |
casticin results in decreased expression of NPAS3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884
|
|
G |
Nrg3 |
neuregulin 3 |
decreases expression |
ISO |
casticin results in decreased expression of NRG3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr16:14,229,270...15,352,505
Ensembl chr16:14,235,157...15,352,368
|
|
G |
Nup205 |
nucleoporin 205 |
decreases expression |
ISO |
casticin results in decreased expression of NUP205 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:63,854,934...63,920,852
Ensembl chr 4:63,854,783...63,920,844
|
|
G |
Nup37 |
nucleoporin 37 |
decreases expression |
ISO |
casticin results in decreased expression of NUP37 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:22,556,544...22,609,622
Ensembl chr 7:22,573,764...22,609,616
|
|
G |
Olig2 |
oligodendrocyte transcription factor 2 |
decreases expression |
ISO |
casticin results in decreased expression of OLIG2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
|
|
G |
Orc5 |
origin recognition complex, subunit 5 |
decreases expression |
ISO |
casticin results in decreased expression of ORC5 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:12,548,007...12,612,611
Ensembl chr 4:12,548,007...12,612,568
|
|
G |
Otub2 |
OTU deubiquitinase, ubiquitin aldehyde binding 2 |
decreases expression |
ISO |
casticin results in decreased expression of OTUB2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:122,545,067...122,563,657
Ensembl chr 6:122,545,061...122,563,644
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
increases expression |
ISO |
casticin results in increased expression of P2RX7 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
casticin results in decreased expression of PAIP1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:51,523,190...51,550,241
Ensembl chr 2:51,522,921...51,550,241
|
|
G |
Pak3 |
p21 (RAC1) activated kinase 3 |
decreases expression |
ISO |
casticin results in decreased expression of PAK3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr X:107,116,308...107,374,342
Ensembl chr X:107,260,898...107,368,314
|
|
G |
Papola |
poly (A) polymerase alpha |
decreases expression |
ISO |
casticin results in decreased expression of PAPOLA mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression |
ISO |
casticin results in increased expression of PARP1 protein |
CTD |
PMID:32270916 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcdha1 |
protocadherin alpha 1 |
increases expression |
ISO |
casticin results in increased expression of PCDHA1 mRNA |
CTD |
PMID:28444820 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Phf10 |
PHD finger protein 10 |
decreases expression |
ISO |
casticin results in decreased expression of PHF10 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:55,952,249...55,968,994
Ensembl chr 1:55,952,253...55,969,038
|
|
G |
Picalm |
phosphatidylinositol binding clathrin assembly protein |
decreases expression |
ISO |
casticin results in decreased expression of PICALM mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:144,056,415...144,138,045
Ensembl chr 1:144,056,721...144,137,557
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
casticin results in decreased expression of PLAU protein |
CTD |
PMID:28444820 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression |
ISO |
casticin results in increased expression of PMP22 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions decreases expression |
ISO |
casticin promotes the reaction [MIR148A mRNA results in decreased expression of POU5F1 mRNA]; DNMT1 protein inhibits the reaction [casticin results in decreased expression of POU5F1 protein]; MIR148A mRNA promotes the reaction [casticin results in decreased expression of POU5F1 mRNA] |
CTD |
PMID:32268151 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
decreases expression |
ISO |
casticin results in decreased expression of PPARD mRNA |
CTD |
PMID:27862857 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
casticin results in increased expression of PPARG mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
ISO |
casticin results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1r11 |
protein phosphatase 1, regulatory (inhibitor) subunit 11 |
decreases expression |
ISO |
casticin results in decreased expression of PPP1R11 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr20:1,601,350...1,604,857
Ensembl chr20:1,601,346...1,604,846
|
|
G |
Ppp6r3 |
protein phosphatase 6, regulatory subunit 3 |
decreases expression |
ISO |
casticin results in decreased expression of PPP6R3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:200,693,128...200,807,578
Ensembl chr 1:200,693,440...200,807,548
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
decreases expression |
ISO |
casticin results in decreased expression of PRKAR2B mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
decreases expression |
ISO |
casticin results in decreased expression of PRKDC protein |
CTD |
PMID:29098808 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Prss44 |
serine protease 44 |
increases expression |
ISO |
casticin results in increased expression of PRSS44 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:110,791,698...110,805,303
Ensembl chr 8:110,791,698...110,805,303
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; casticin inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:38309612 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases expression |
ISO |
casticin results in decreased expression of PTK2 protein |
CTD |
PMID:28444820 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptpra |
protein tyrosine phosphatase, receptor type, A |
increases expression |
ISO |
casticin results in increased expression of PTPRA mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:117,650,146...117,759,744
Ensembl chr 3:117,650,183...117,759,728
|
|
G |
Ptprd |
protein tyrosine phosphatase, receptor type, D |
decreases expression |
ISO |
casticin results in decreased expression of PTPRD mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:90,046,993...90,698,977 NCBI chr 5:91,122,354...91,641,754
Ensembl chr 5:90,048,966...92,369,396
|
|
G |
Ptprf |
protein tyrosine phosphatase, receptor type, F |
decreases expression |
ISO |
casticin results in decreased expression of PTPRF mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:131,741,959...131,824,000
Ensembl chr 5:131,742,754...131,810,023
|
|
G |
Qki |
QKI, KH domain containing RNA binding |
decreases expression |
ISO |
casticin results in decreased expression of QKI mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:50,387,716...50,501,568
Ensembl chr 1:50,387,698...50,498,831
|
|
G |
Rapgef4 |
Rap guanine nucleotide exchange factor 4 |
decreases expression |
ISO |
casticin results in decreased expression of RAPGEF4 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316
|
|
G |
Rars1 |
arginyl-tRNA synthetase 1 |
decreases expression |
ISO |
casticin results in decreased expression of RARS1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:20,270,744...20,295,192
Ensembl chr10:20,270,483...20,295,196
|
|
G |
Rbmx2 |
RNA binding motif protein, X-linked 2 |
decreases expression |
ISO |
casticin results in decreased expression of RBMX2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr X:127,888,514...127,896,239
Ensembl chr X:127,888,438...127,896,869
|
|
G |
Rcor3 |
REST corepressor 3 |
decreases expression |
ISO |
casticin results in decreased expression of RCOR3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr13:103,624,966...103,665,565
Ensembl chr13:103,624,971...103,665,565
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
casticin results in decreased expression of RELA protein |
CTD |
PMID:28444820 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rexo2 |
RNA exonuclease 2 |
decreases expression |
ISO |
casticin results in decreased expression of REXO2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:48,811,900...48,823,622
Ensembl chr 8:48,811,900...48,823,622
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
ISO |
casticin results in decreased expression of RHOA protein |
CTD |
PMID:28444820 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl22l1 |
ribosomal protein L22 like 1 |
decreases expression |
ISO |
casticin results in decreased expression of RPL22L1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:111,754,687...111,756,623
Ensembl chr 2:111,754,687...111,756,625
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
increases expression |
ISO |
casticin results in increased expression of S100A13 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:175,999,439...176,005,933
|
|
G |
Scn1b |
sodium voltage-gated channel beta subunit 1 |
increases expression |
ISO |
casticin results in increased expression of SCN1B mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:86,353,917...86,363,820
Ensembl chr 1:86,353,917...86,363,739
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
increases expression |
ISO |
casticin results in increased expression of SLC31A1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
decreases expression |
ISO |
casticin results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Smad1 |
SMAD family member 1 |
increases expression |
ISO |
casticin results in increased expression of SMAD1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651
|
|
G |
Smad3 |
SMAD family member 3 |
increases expression |
ISO |
casticin results in increased expression of SMAD3 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snrpg |
small nuclear ribonucleoprotein polypeptide G |
decreases expression |
ISO |
casticin results in decreased expression of SNRPG mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:118,812,278...118,819,827
Ensembl chr 4:118,812,252...118,819,826 Ensembl chr X:118,812,252...118,819,826
|
|
G |
Snw1 |
SNW domain containing 1 |
decreases expression |
ISO |
casticin results in decreased expression of SNW1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 6:107,095,450...107,119,536
Ensembl chr 6:107,095,457...107,119,536
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
ISO |
casticin promotes the reaction [Fluorouracil results in increased expression of SOD1 protein]; Fluorouracil promotes the reaction [casticin results in increased expression of SOD1 protein] |
CTD |
PMID:32270916 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
casticin results in decreased expression of SOS1 protein |
CTD |
PMID:28444820 |
|
NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression increases expression |
ISO |
casticin results in decreased expression of SPARC mRNA casticin results in increased expression of SPARC mRNA |
CTD |
PMID:27862857 PMID:28444820 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Sparcl1 |
SPARC like 1 |
increases expression |
ISO |
casticin results in increased expression of SPARCL1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr14:5,632,816...5,663,866
Ensembl chr14:5,632,569...5,663,865
|
|
G |
St13 |
ST13, Hsp70 interacting protein |
increases expression |
ISO |
casticin results in increased expression of ST13 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 7:112,891,007...112,925,727
Ensembl chr 7:112,844,375...112,925,945
|
|
G |
St3gal3 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 3 |
decreases expression |
ISO |
casticin results in decreased expression of ST3GAL3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:131,470,348...131,670,794
Ensembl chr 5:131,470,348...131,670,810
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
decreases expression |
ISO |
casticin results in decreased expression of STRBP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 3:21,328,310...21,467,753
Ensembl chr 3:21,337,855...21,414,949
|
|
G |
Sugp1 |
SURP and G patch domain containing 1 |
decreases expression |
ISO |
casticin results in decreased expression of SUGP1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr16:19,352,659...19,383,533
Ensembl chr16:19,351,793...19,383,756
|
|
G |
Syncrip |
synaptotagmin binding, cytoplasmic RNA interacting protein |
decreases expression |
ISO |
casticin results in decreased expression of SYNCRIP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
|
|
G |
Syt9 |
synaptotagmin 9 |
decreases expression |
ISO |
casticin results in decreased expression of SYT9 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:161,275,882...161,456,384
Ensembl chr 1:161,275,734...161,455,007
|
|
G |
Tab2 |
TGF-beta activated kinase 1/MAP3K7 binding protein 2 |
decreases expression |
ISO |
casticin results in decreased expression of TAB2 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 1:2,375,026...2,425,115
Ensembl chr 1:2,375,490...2,424,756
|
|
G |
Tcf7 |
transcription factor 7 |
decreases expression |
ISO |
casticin results in decreased expression of TCF7 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535
|
|
G |
Thra |
thyroid hormone receptor alpha |
decreases expression |
ISO |
casticin results in decreased expression of THRA mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
increases expression |
ISO |
casticin results in increased expression of TIMP2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tlk2 |
tousled-like kinase 2 |
decreases expression |
ISO |
casticin results in decreased expression of TLK2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:90,154,449...90,248,562
Ensembl chr10:90,156,813...90,248,561
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression |
ISO |
casticin results in decreased expression of TLR4 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tmbim4 |
transmembrane BAX inhibitor motif containing 4 |
increases expression |
ISO |
casticin results in increased expression of TMBIM4 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 7:55,718,690...55,733,277
Ensembl chr 7:55,718,699...55,742,773
|
|
G |
Tmem45b |
transmembrane protein 45b |
increases expression |
ISO |
casticin results in increased expression of TMEM45B mRNA |
CTD |
PMID:27862857 |
|
NCBI chr 8:29,865,276...29,910,453
Ensembl chr 8:29,865,278...29,910,453
|
|
G |
Tmsb10 |
thymosin, beta 10 |
increases expression |
ISO |
casticin results in increased expression of TMSB10 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:105,009,959...105,011,095
Ensembl chr 4:105,009,212...105,011,028
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
casticin inhibits the reaction [IL1B protein results in increased secretion of TNF protein] |
CTD |
PMID:38309612 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
casticin results in increased expression of TNFSF10 protein |
CTD |
PMID:27862857 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnpo1 |
transportin 1 |
decreases expression |
ISO |
casticin results in decreased expression of TNPO1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:30,207,529...30,300,162
Ensembl chr 2:30,211,510...30,300,375
|
|
G |
Tor1aip2 |
torsin 1A interacting protein 2 |
decreases expression |
ISO |
casticin results in decreased expression of TOR1AIP2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr13:68,225,226...68,256,536
Ensembl chr13:68,230,009...68,256,536 Ensembl chr13:68,230,009...68,256,536
|
|
G |
Tp53 |
tumor protein p53 |
increases expression decreases expression |
ISO |
casticin results in increased expression of TP53 protein modified form casticin results in decreased expression of TP53 protein |
CTD |
PMID:29098808 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
ISO |
casticin results in increased expression of TPI1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpra1 |
transmembrane protein adipocyte associated 1 |
increases expression |
ISO |
casticin results in increased expression of TPRA1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:121,364,093...121,375,275
Ensembl chr 4:121,364,091...121,375,269
|
|
G |
Tra2b |
transformer 2 beta |
decreases expression |
ISO |
casticin results in decreased expression of TRA2B mRNA |
CTD |
PMID:28444820 |
|
NCBI chr11:78,788,880...78,807,252
Ensembl chr11:78,788,884...78,807,249
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
increases expression |
ISO |
casticin results in increased expression of TRAP1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981
|
|
G |
Trio |
trio Rho guanine nucleotide exchange factor |
increases expression |
ISO |
casticin results in increased expression of TRIO mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:78,505,069...78,801,384
Ensembl chr 2:78,505,070...78,803,135
|
|
G |
Ube2d3 |
ubiquitin-conjugating enzyme E2D 3 |
decreases expression |
ISO |
casticin results in decreased expression of UBE2D3 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:223,868,397...223,899,606
Ensembl chr 2:223,868,730...223,898,081
|
|
G |
Ube2f |
ubiquitin-conjugating enzyme E2F (putative) |
decreases expression |
ISO |
casticin results in decreased expression of UBE2F mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 9:91,845,975...91,881,145
Ensembl chr 9:91,845,987...91,880,594
|
|
G |
Ube2w |
ubiquitin-conjugating enzyme E2W |
decreases expression |
ISO |
casticin results in decreased expression of UBE2W mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 5:2,690,742...2,754,491
Ensembl chr 5:2,690,763...2,814,965
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
casticin results in decreased expression of VEGFA mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vezf1 |
vascular endothelial zinc finger 1 |
decreases expression |
ISO |
casticin results in decreased expression of VEZF1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:72,859,669...72,876,111
Ensembl chr10:72,859,877...72,876,111
|
|
G |
Vim |
vimentin |
decreases expression increases expression |
ISO |
casticin results in decreased expression of VIM mRNA casticin results in increased expression of VIM mRNA |
CTD |
PMID:27862857 PMID:28444820 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vldlr |
very low density lipoprotein receptor |
decreases expression |
ISO |
casticin results in decreased expression of VLDLR mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
G |
Wac |
WW domain containing adaptor with coiled-coil |
decreases expression |
ISO |
casticin results in decreased expression of WAC mRNA |
CTD |
PMID:28444820 |
|
NCBI chr17:55,922,686...55,984,286
Ensembl chr17:55,923,123...55,982,301
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
decreases expression |
ISO |
casticin results in decreased expression of WEE1 protein |
CTD |
PMID:29098808 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Wnt5a |
Wnt family member 5A |
decreases expression |
ISO |
casticin results in decreased expression of WNT5A mRNA |
CTD |
PMID:27862857 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wsb1 |
WD repeat and SOCS box-containing 1 |
decreases expression |
ISO |
casticin results in decreased expression of WSB1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr10:64,202,761...64,219,039
Ensembl chr10:64,202,763...64,219,019
|
|
G |
Wtap |
WT1 associated protein |
decreases expression |
ISO |
casticin results in decreased expression of WTAP mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:47,665,965...47,691,067
Ensembl chr 1:47,665,965...47,691,065
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
casticin results in increased expression of XBP1 mRNA |
CTD |
PMID:27862857 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
casticin results in decreased expression of XIAP protein |
CTD |
PMID:29098808 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Ywhab |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta |
increases expression |
ISO |
casticin results in increased expression of YWHAB protein |
CTD |
PMID:29098808 |
|
NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105
|
|
G |
Ywhag |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma |
decreases expression |
ISO |
casticin results in decreased expression of YWHAG mRNA |
CTD |
PMID:28444820 |
|
NCBI chr12:20,744,500...20,772,828
Ensembl chr12:20,744,535...20,772,827
|
|
G |
Zbtb18 |
zinc finger and BTB domain containing 18 |
decreases expression |
ISO |
casticin results in decreased expression of ZBTB18 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr13:89,439,501...89,447,958
Ensembl chr13:89,439,420...89,448,862
|
|
G |
Zfhx4 |
zinc finger homeobox 4 |
decreases expression |
ISO |
casticin results in decreased expression of ZFHX4 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:96,224,763...96,408,245
Ensembl chr 2:96,224,767...96,408,228
|
|
G |
Zfp384 |
zinc finger protein 384 |
decreases expression |
ISO |
casticin results in decreased expression of ZFP384 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 4:157,810,263...157,840,052
Ensembl chr 4:157,810,352...157,839,766
|
|
G |
Zfp711 |
zinc finger protein 711 |
decreases expression |
ISO |
casticin results in decreased expression of ZFP711 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr X:77,646,300...77,679,398
Ensembl chr X:77,646,558...77,678,045
|
|
G |
Zfr |
zinc finger RNA binding protein |
decreases expression |
ISO |
casticin results in decreased expression of ZFR mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322
|
|
G |
Zkscan1 |
zinc finger with KRAB and SCAN domains 1 |
increases expression |
ISO |
casticin results in increased expression of ZKSCAN1 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr12:16,966,287...16,987,680
Ensembl chr12:16,966,654...16,983,865
|
|
G |
Zscan2 |
zinc finger and SCAN domain containing 2 |
increases expression |
ISO |
casticin results in increased expression of ZSCAN2 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 1:134,833,701...134,848,957
Ensembl chr 1:134,833,871...134,848,952
|
|
G |
Zswim6 |
zinc finger, SWIM-type containing 6 |
increases expression |
ISO |
casticin results in increased expression of ZSWIM6 mRNA |
CTD |
PMID:28444820 |
|
NCBI chr 2:39,211,131...39,378,877
Ensembl chr 2:39,212,949...39,378,924
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; 5,7-dimethoxyflavone inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 5,7-dimethoxyflavone inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]] |
CTD |
PMID:34217736 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of BAX protein |
CTD |
PMID:21554863 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2L1 protein] |
CTD |
PMID:21554863 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
5,7-dimethoxyflavone promotes the reaction [Diethylnitrosamine results in increased expression of CASP3 protein] |
CTD |
PMID:21554863 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein] |
CTD |
PMID:24134915 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 protein] |
CTD |
PMID:21554863 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Csnk2b |
casein kinase 2 beta |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CSNK2B mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CSNK2B protein] |
CTD |
PMID:21554863 |
|
NCBI chr20:3,700,363...3,705,331
Ensembl chr20:3,698,733...3,707,133
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine affects the localization of CTNNB1 protein modified form]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:21554863 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of and results in increased activity of CYP1A1 protein]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] 5,7-dimethoxyflavone results in decreased activity of CYP1A1 protein |
CTD |
PMID:15661813 PMID:15905203 PMID:16484233 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions decreases activity |
ISO |
5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1B1 protein]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein] 5,7-dimethoxyflavone results in decreased activity of CYP1B1 protein |
CTD |
PMID:15905203 PMID:16484233 PMID:16530937 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
5,7-dimethoxyflavone promotes the reaction [Diethylnitrosamine results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:21554863 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; 5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; 5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:24134915 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
5,7-dimethoxyflavone inhibits the reaction [IL1B protein results in increased secretion of IL6 protein] |
CTD |
PMID:24134915 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of NOS2 protein] |
CTD |
PMID:21554863 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 protein] |
CTD |
PMID:21554863 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of RELA mRNA]; 5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of RELA protein modified form] |
CTD |
PMID:21554863 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
[5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [5,7-dimethoxyflavone co-treated with Diethylnitrosamine] results in increased expression of TP53 protein |
CTD |
PMID:21554863 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Wnt3a |
Wnt family member 3A |
multiple interactions |
EXP |
5,7-dimethoxyflavone inhibits the reaction [Diethylnitrosamine results in increased expression of WNT3A protein] |
CTD |
PMID:21554863 |
|
NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324
|
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
chrysosplenetin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects activity |
ISO |
chrysosplenetin affects the activity of CYP3A4 protein |
CTD |
PMID:29753067 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL2 protein] |
CTD |
PMID:33949057 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein] |
CTD |
PMID:33949057 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein] |
CTD |
PMID:33949057 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of MCL1 protein] |
CTD |
PMID:33949057 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of MPO protein] |
CTD |
PMID:33949057 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of MYD88 protein] |
CTD |
PMID:33949057 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] |
CTD |
PMID:33949057 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:33949057 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RELA protein] |
CTD |
PMID:33949057 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TLR4 protein] |
CTD |
PMID:33949057 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; cirsilineol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein] |
CTD |
PMID:33949057 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases metabolic processing increases expression |
ISO |
cirsiliol results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased metabolism of cirsiliol cirsiliol results in increased expression of CYP1A1 mRNA |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression increases metabolic processing decreases activity |
ISO |
cirsiliol results in increased expression of CYP1B1 mRNA CYP1B1 protein results in increased metabolism of cirsiliol cirsiliol results in decreased activity of CYP1B1 protein |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
dimethoxyflavone inhibits the reaction [benzo[a]pyrene increases expression of FGF9 mRNA and protein in lung cell] |
RGD |
PMID:19358281 |
RGD:152177688 |
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand affects the expression of ACP5 mRNA] |
CTD |
PMID:36563736 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP1 protein modified form] |
CTD |
PMID:35191607 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]] |
CTD |
PMID:35191607 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases response to substance multiple interactions |
ISO |
diosmetin results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased susceptibility to diosmetin [CYP1A1 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin |
CTD |
PMID:10781868 PMID:21482471 PMID:33727136 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity multiple interactions increases response to substance |
ISO |
diosmetin results in decreased activity of CYP1A2 protein [CYP1A2 protein results in increased susceptibility to Luteolin] which results in decreased abundance of diosmetin CYP1A2 protein results in increased susceptibility to diosmetin |
CTD |
PMID:28867436 PMID:33727136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP1B1 protein |
CTD |
PMID:10781868 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2C19 protein |
CTD |
PMID:28867436 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2C8 protein |
CTD |
PMID:28867436 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
diosmetin results in decreased activity of CYP2E1 protein |
CTD |
PMID:28867436 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; diosmetin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 4-hydroxymidazolam] |
CTD |
PMID:18191104 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of HMOX1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of HMOX1 protein] |
CTD |
PMID:35191607 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL18 protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL18 protein] |
CTD |
PMID:35191607 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of IL1B protein]; diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of IL1B protein] |
CTD |
PMID:35191607 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of KEAP1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]] |
CTD |
PMID:35191607 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:36563736 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:36563736 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:36563736 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36563736 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [RANK Ligand affects the expression of NFATC1 mRNA] |
CTD |
PMID:36563736 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NFE2L2 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]; KEAP1 protein inhibits the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of CASP3 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of KEAP1 protein]]; NFE2L2 protein promotes the reaction [diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of and affects the localization of NFE2L2 protein]] |
CTD |
PMID:35191607 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16934226 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NLRP3 protein] |
CTD |
PMID:35191607 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:16934226 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
diosmetin promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of NQO1 protein]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 mRNA]; diosmetin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of NQO1 protein] |
CTD |
PMID:35191607 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]; KEAP1 protein inhibits the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]]; NFE2L2 protein promotes the reaction [diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PARP1 protein modified form]] |
CTD |
PMID:35191607 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
diosmetin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
diosmetin inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of PYCARD protein] |
CTD |
PMID:35191607 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
EXP |
[diosmetin results in decreased activity of SLC16A1 protein] which results in decreased uptake of Sodium Oxybate |
CTD |
PMID:17108059 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:28867436 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:28867436 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
diosmetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:16934226 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Diosmin binds to and results in increased activity of AHR protein |
CTD |
PMID:14644660 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ar |
androgen receptor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of AR protein] |
CTD |
PMID:31797688 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of BAD protein] |
CTD |
PMID:21477647 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of BAX protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
[Diosmin co-treated with Lipopolysaccharides] results in increased expression of BCL2 protein Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BCL2 protein] |
CTD |
PMID:21477647 PMID:32061149 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP3 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of CASP3 protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 PMID:32061149 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP7 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of CASP9 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [Testosterone Propionate results in decreased activity of CAT protein] |
CTD |
PMID:22056647 PMID:23665045 PMID:31797688 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of CEACAM1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of CYP2E1 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of ENO2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of and results in decreased activity of GPX1 protein] |
CTD |
PMID:35920545 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in decreased expression of GSR protein]; Diosmin inhibits the reaction [Testosterone Propionate results in decreased activity of GSR protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in decreased expression of GSR protein] |
CTD |
PMID:23665045 PMID:31797688 PMID:32061149 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of IL6 protein] Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of IL6 protein] |
CTD |
PMID:31797688 PMID:32061149 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of KLK3 protein] |
CTD |
PMID:31797688 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of MKI67 protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of MKI67 protein] |
CTD |
PMID:23665045 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Diosmin inhibits the reaction [Acetic Acid results in increased activity of MPO protein] |
CTD |
PMID:29187079 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of NOS2 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of PARP1 protein] |
CTD |
PMID:32061149 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of PCNA protein]; Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PCNA protein] |
CTD |
PMID:23665045 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGER2 protein] |
CTD |
PMID:35920545 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein]; Diosmin inhibits the reaction [Testosterone Propionate results in increased expression of PTGS2 protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of PTGS2 protein] |
CTD |
PMID:23665045 PMID:29187079 PMID:31797688 PMID:32061149 PMID:35920545 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of RELA protein] |
CTD |
PMID:32061149 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased expression of TNF protein]; Diosmin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Diosmin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21477647 PMID:23665045 PMID:29187079 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Diosmin inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of TP53 protein] |
CTD |
PMID:23665045 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP ISO |
Diosmin inhibits the reaction [2-Acetylaminofluorene results in increased activity of XDH protein]; Diosmin inhibits the reaction [Testosterone Propionate results in increased activity of XDH protein] Diosmin inhibits the reaction [Benzo(a)pyrene results in increased expression of XDH protein] |
CTD |
PMID:23665045 PMID:31797688 PMID:32061149 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in decreased expression of ABCG2 protein] |
CTD |
PMID:38052408 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of CCL2 mRNA] |
CTD |
PMID:21565208 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases activity |
ISO |
[[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam |
CTD |
PMID:31756459 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL1B mRNA] eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL1B protein] |
CTD |
PMID:21565208 PMID:38052408 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 mRNA] eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased secretion of IL6 protein] |
CTD |
PMID:21565208 PMID:38052408 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:21565208 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of NOS2 mRNA]; eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of NOS2 protein] |
CTD |
PMID:21565208 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 mRNA]; eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] |
CTD |
PMID:21565208 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of RELA protein] |
CTD |
PMID:21565208 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [SLC2A1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] |
CTD |
PMID:36870413 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
multiple interactions |
EXP |
eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased expression of SLC2A12 protein] |
CTD |
PMID:38052408 |
|
NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:22,804,418...22,860,971
|
|
G |
Slc2a9 |
solute carrier family 2 member 9 |
multiple interactions |
EXP |
eupatilin inhibits the reaction [[potassium oxonate co-treated with Hypoxanthine] results in increased expression of SLC2A9 protein] |
CTD |
PMID:38052408 |
|
NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA] |
CTD |
PMID:21565208 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases response to substance increases metabolic processing decreases activity increases expression |
ISO |
CYP1A1 protein results in increased susceptibility to eupatorin CYP1A1 protein results in increased metabolism of eupatorin analog eupatorin analog results in decreased activity of CYP1A1 protein eupatorin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:18454852 PMID:19601638 PMID:21482471 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing increases expression decreases activity |
ISO |
CYP1B1 protein results in increased metabolism of eupatorin analog eupatorin results in increased expression of CYP1B1 mRNA eupatorin results in decreased activity of CYP1B1 protein |
CTD |
PMID:19601638 PMID:21482471 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2C19 protein |
CTD |
PMID:21093571 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP2D6 protein |
CTD |
PMID:21276781 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
eupatorin results in decreased activity of CYP3A4 protein |
CTD |
PMID:21276781 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
gardenin B results in decreased expression of BCL2 protein |
CTD |
PMID:27423764 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
gardenin B results in increased cleavage of and results in increased activity of CASP2 protein |
CTD |
PMID:27423764 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
gardenin B results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:27423764 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
gardenin B results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:27423764 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
gardenin B results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:27423764 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
gardenin B results in increased cleavage of PARP1 protein |
CTD |
PMID:27423764 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP1 protein] |
CTD |
PMID:34481870 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased activity of CASP3 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased activity of CASP3 protein]] |
CTD |
PMID:34481870 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing decreases activity |
ISO |
CYP1A1 protein results in increased metabolism of genkwanin genkwanin results in decreased activity of CYP1A1 protein |
CTD |
PMID:19666078 PMID:21482471 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP1A2 protein results in increased metabolism of genkwanin |
CTD |
PMID:19666078 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing multiple interactions |
ISO |
CYP1B1 protein results in increased metabolism of genkwanin [CYP1B1 protein results in increased metabolism of genkwanin] which results in increased chemical synthesis of Apigenin |
CTD |
PMID:19666078 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]] |
CTD |
PMID:34481870 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL6 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL6 protein]] |
CTD |
PMID:34481870 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MYD88 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MYD88 protein]] |
CTD |
PMID:34481870 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NLRP3 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NLRP3 protein]] |
CTD |
PMID:34481870 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]] |
CTD |
PMID:34481870 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TLR4 protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased activity of CASP3 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MYD88 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NLRP3 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL1B protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of IL6 protein]]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]] |
CTD |
PMID:34481870 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]; TLR4 protein inhibits the reaction [genkwanin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]] |
CTD |
PMID:34481870 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein] ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:25968939 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein] |
CTD |
PMID:25968939 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein] |
CTD |
PMID:25968939 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ftl1 |
ferritin light chain 1 |
decreases expression |
ISO |
ginkgetin results in decreased expression of FTL1 protein ginkgetin results in decreased expression of FTL protein |
CTD |
PMID:25968939 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
ginkgetin results in increased expression of TFRC protein |
CTD |
PMID:25968939 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] |
CTD |
PMID:25968939 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein] |
CTD |
PMID:30055130 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA] |
CTD |
PMID:30055130 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cxcl17 |
C-X-C motif chemokine ligand 17 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CXCL17 mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr 1:80,984,751...80,996,842
Ensembl chr 1:80,984,964...80,996,726
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [Imiquimod results in increased expression of CXCL1 mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CXCL17 mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of IL18BP mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of IL1B mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of TNF mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK8 protein]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:32679548 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
hispidulin inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18bp |
interleukin 18 binding protein |
multiple interactions |
ISO |
hispidulin inhibits the reaction [Imiquimod results in increased expression of IL18BP mRNA] hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of IL18BP mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr 1:156,372,923...156,374,963
Ensembl chr 1:156,372,883...156,374,963
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
hispidulin inhibits the reaction [Imiquimod results in increased expression of IL1B mRNA] hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of IL1B mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL4 mRNA] |
CTD |
PMID:31195760 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [Imiquimod results in increased expression of IL6 mRNA] |
CTD |
PMID:32679548 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of ADIPOQ protein]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein] |
CTD |
PMID:30055130 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
hispidulin decreases phoshphorylation of JAK2 protein in colon and colorectum |
RGD |
PMID:29575334 |
RGD:149735333 |
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein] hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:22759588 PMID:32679548 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein] hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:22759588 PMID:32679548 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:32679548 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
hispidulin inhibits the reaction [Imiquimod results in increased expression of MPO protein] |
CTD |
PMID:32679548 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of PPARG protein] |
CTD |
PMID:30055130 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:32679548 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
hispidulin inhibits the reaction [SLC2A1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] |
CTD |
PMID:36870413 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slco1c1 |
solute carrier organic anion transporter family, member 1c1 |
decreases activity multiple interactions |
EXP |
hispidulin results in decreased activity of SLCO1B1 protein [hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate |
CTD |
PMID:32259555 |
|
NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289
|
|
G |
Syn1 |
synapsin I |
affects response to substance |
ISO |
SYN1 protein affects the susceptibility to hispidulin |
CTD |
PMID:22759588 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
hispidulin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CXCL17 mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of IL18BP mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of IL1B mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of TNF mRNA]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK1 protein]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK3 protein]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of MAPK8 protein]; hispidulin inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein] hispidulin inhibits the reaction [Imiquimod results in increased expression of TNF protein] |
CTD |
PMID:31195760 PMID:32679548 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport increases activity multiple interactions decreases expression increases expression |
ISO |
ABCB1 protein results in increased transport of 3-methylquercetin 3-methylquercetin results in increased activity of ABCB1 protein 3-methylquercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 3-methylquercetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; 3-methylquercetin promotes the reaction [Quercetin results in increased activity of ABCB1 protein] 3-methylquercetin results in decreased expression of ABCB1 protein 3-methylquercetin results in increased expression of ABCB1 mRNA |
CTD |
PMID:15969930 PMID:26238175 PMID:34217736 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
3-methylquercetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:27151496 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein] |
CTD |
PMID:17374653 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein] |
CTD |
PMID:19794518 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO EXP |
3-methylquercetin results in decreased phosphorylation of AKT1 protein 3-methylquercetin affects the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12826665 PMID:19222219 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of BCL2 mRNA; 3-methylquercetin results in decreased expression of BCL2 protein |
CTD |
PMID:22992727 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of BCL2L1 mRNA; 3-methylquercetin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22992727 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions increases activity |
ISO EXP |
3-methylquercetin results in decreased expression of CASP3 protein 3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein] 3-methylquercetin results in increased activity of CASP3 protein |
CTD |
PMID:12826665 PMID:19222219 PMID:22992727 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of CASP9 protein |
CTD |
PMID:22992727 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT protein |
CTD |
PMID:19222219 PMID:25716194 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of CCL3 mRNA |
CTD |
PMID:20579867 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of CCND1 mRNA; 3-methylquercetin results in decreased expression of CCND1 protein |
CTD |
PMID:22992727 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of CDH1 mRNA; 3-methylquercetin results in increased expression of CDH1 protein |
CTD |
PMID:37537191 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27151496 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:21329749 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:19794518 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
3-methylquercetin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:26238175 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Esr1 |
estrogen receptor 1 |
affects binding |
ISO |
3-methylquercetin binds to ESR1 protein |
CTD |
PMID:14706564 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
affects binding |
ISO |
3-methylquercetin binds to ESR2 protein |
CTD |
PMID:14706564 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC protein 3-methylquercetin results in increased expression of GCLC mRNA; 3-methylquercetin results in increased expression of GCLC protein |
CTD |
PMID:24211276 PMID:25716194 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:27151496 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 protein 3-methylquercetin results in increased expression of HMOX1 mRNA; 3-methylquercetin results in increased expression of HMOX1 protein 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of HMOX1 mRNA]; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein |
CTD |
PMID:24211276 PMID:24337631 PMID:25716194 PMID:27151496 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL1B mRNA |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL6 mRNA |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of MAPK14 mRNA; 3-methylquercetin results in decreased expression of MAPK14 protein |
CTD |
PMID:36819991 PMID:37537191 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19222219 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of MIR155 mRNA] |
CTD |
PMID:20579867 |
|
NCBI chr11:37,261,114...37,261,178
Ensembl chr11:23,774,654...23,774,718
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
3-methylquercetin results in decreased phosphorylation of MTOR protein |
CTD |
PMID:37537191 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:17374653 PMID:18436224 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects response to substance multiple interactions affects localization increases activity |
ISO |
NFE2L2 protein affects the susceptibility to 3-methylquercetin 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; 3-methylquercetin affects the localization of and results in increased phosphorylation of and results in increased activity of NFE2L2 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased abundance of Glutathione; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] 3-methylquercetin affects the localization of NFE2L2 protein [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; NFE2L2 protein affects the reaction [3-methylquercetin results in decreased susceptibility to tert-Butylhydroperoxide] |
CTD |
PMID:24211276 PMID:27151496 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:23774260 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of NOS2 mRNA |
CTD |
PMID:16213685 PMID:18178435 PMID:18274639 PMID:20579867 PMID:23774260 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipids results in decreased expression of NOS3] |
CTD |
PMID:16891912 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA |
CTD |
PMID:24211276 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
3-methylquercetin binds to and results in increased activity of NR1I2 protein 3-methylquercetin results in increased activity of NR1I2 protein |
CTD |
PMID:26238175 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipids results in increased expression of OLR1] |
CTD |
PMID:16891912 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
3-methylquercetin results in increased cleavage of PARP1 protein |
CTD |
PMID:22992727 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of PECAM1 protein |
CTD |
PMID:22992727 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of PON1 mRNA |
CTD |
PMID:20228421 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
increases expression |
ISO |
3-methylquercetin results in increased expression of PON2 mRNA |
CTD |
PMID:19865538 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases activity |
ISO |
3-methylquercetin results in increased activity of PPARD protein |
CTD |
PMID:22992727 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [3-methylquercetin results in increased activity of PPARG protein]; 3-methylquercetin binds to and results in increased activity of PPARG protein 3-methylquercetin results in increased expression of PPARG protein |
CTD |
PMID:22992727 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkcd |
protein kinase C, delta |
increases phosphorylation |
ISO |
3-methylquercetin results in increased phosphorylation of PRKCD protein |
CTD |
PMID:24211276 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
ISO EXP |
3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Acetylcysteine promotes the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]]; tin protoporphyrin IX inhibits the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]] 3-methylquercetin results in decreased activity of PTGS2 protein 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] |
CTD |
PMID:15292928 PMID:21341175 PMID:24337631 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:18274639 PMID:20579867 PMID:23774260 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] |
CTD |
PMID:27151496 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA |
CTD |
PMID:24211276 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:27151496 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]] |
CTD |
PMID:27151496 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of TFF1 mRNA |
CTD |
PMID:14706564 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]] |
CTD |
PMID:27151496 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
3-methylquercetin results in increased expression of TYR protein |
CTD |
PMID:24853321 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of TYRP1 protein |
CTD |
PMID:24853321 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of VIM mRNA; 3-methylquercetin results in decreased expression of VIM protein |
CTD |
PMID:37537191 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
jaceosidin results in increased expression of and results in increased activity of BAX protein |
CTD |
PMID:27729209 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
jaceosidin results in increased activity of CASP3 protein |
CTD |
PMID:27729209 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
jaceosidin results in decreased expression of CFLAR mRNA; jaceosidin results in decreased expression of CFLAR protein CFLAR protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; RELA protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]; SP1 protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein] |
CTD |
PMID:27729209 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression multiple interactions |
ISO |
jaceosidin results in decreased expression of MCL1 mRNA; jaceosidin results in decreased expression of MCL1 protein MCL1 protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; RELA protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein]; SP1 protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein] |
CTD |
PMID:27729209 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
jaceosidin results in increased cleavage of PARP1 protein benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; CFLAR protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein]; MCL1 protein inhibits the reaction [jaceosidin results in increased cleavage of PARP1 protein] |
CTD |
PMID:27729209 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
RELA protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]; RELA protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein] |
CTD |
PMID:27729209 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
SP1 protein inhibits the reaction [jaceosidin results in decreased expression of CFLAR protein]; SP1 protein inhibits the reaction [jaceosidin results in decreased expression of MCL1 protein] |
CTD |
PMID:27729209 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
kaempferide inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]; kaempferide inhibits the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Daunorubicin]] |
CTD |
PMID:34217736 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
kaempferide results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:21865046 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
kaempferide binds to and affects the folding of SOD1 protein mutant form |
CTD |
PMID:30260512 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
kaempferide results in increased expression of VEGFA mRNA |
CTD |
PMID:21865046 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
nevadensin results in increased activity of CASP3 protein |
CTD |
PMID:34635930 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
nevadensin results in increased activity of CASP9 protein |
CTD |
PMID:34635930 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [nevadensin results in increased abundance of Hydrogen Peroxide] |
CTD |
PMID:34635930 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
nevadensin results in decreased activity of TOP1 protein |
CTD |
PMID:34635930 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases activity |
ISO |
nevadensin results in decreased activity of TOP2A protein |
CTD |
PMID:34635930 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
nobiletin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased import of Daunorubicin] |
CTD |
PMID:18955043 PMID:30790579 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased import of fluorexon] |
CTD |
PMID:18955043 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
[nobiletin co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:29687528 PMID:32344236 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO EXP |
nobiletin results in increased expression of ASNS mRNA; nobiletin results in increased expression of ASNS protein |
CTD |
PMID:23321314 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
nobiletin inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein] nobiletin inhibits the reaction [Arsenic results in increased expression of BAX protein]; nobiletin inhibits the reaction [nonylphenol results in increased expression of BAX mRNA] |
CTD |
PMID:29687528 PMID:32815738 PMID:36850985 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
nobiletin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] nobiletin inhibits the reaction [Arsenic results in decreased expression of BCL2 protein]; nobiletin inhibits the reaction [nonylphenol results in decreased expression of BCL2 mRNA] |
CTD |
PMID:29687528 PMID:32815738 PMID:36850985 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
AGN 193109 inhibits the reaction [nobiletin results in decreased expression of and results in increased cleavage of CASP3 protein]; nobiletin results in decreased expression of and results in increased cleavage of CASP3 protein nobiletin inhibits the reaction [Arsenic results in increased expression of CASP3 protein]; nobiletin inhibits the reaction [nonylphenol results in increased expression of CASP3 mRNA] |
CTD |
PMID:32815738 PMID:33058988 PMID:36850985 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
AGN 193109 inhibits the reaction [nobiletin results in increased cleavage of CASP8 protein] |
CTD |
PMID:33058988 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO EXP |
AGN 193109 inhibits the reaction [nobiletin results in decreased expression of and results in increased cleavage of CASP9 protein]; nobiletin results in decreased expression of and results in increased cleavage of CASP9 protein nobiletin inhibits the reaction [Arsenic results in increased expression of CASP9 protein] |
CTD |
PMID:33058988 PMID:36850985 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
nobiletin inhibits the reaction [Arsenic results in decreased activity of CAT protein]; nobiletin inhibits the reaction [nonylphenol results in decreased activity of CAT protein] |
CTD |
PMID:32815738 PMID:36850985 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of CCNA2 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of CCNE2 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
nobiletin results in decreased expression of CD74 mRNA |
CTD |
PMID:18818744 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing increases expression multiple interactions |
ISO |
CYP1A1 protein results in increased metabolism of nobiletin nobiletin results in increased expression of CYP1A1 protein nobiletin inhibits the reaction [DDT results in increased expression of CYP1A1 mRNA]; nobiletin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:20865247 PMID:22743247 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP1A2 protein results in increased metabolism of nobiletin |
CTD |
PMID:22743247 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
nobiletin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:22743247 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases activity multiple interactions |
ISO |
nobiletin results in increased activity of CYP3A4 protein [[nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [nobiletin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam |
CTD |
PMID:31756459 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO EXP |
nobiletin results in increased expression of DDIT3 mRNA; nobiletin results in increased expression of DDIT3 protein |
CTD |
PMID:23321314 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Depdc1 |
DEP domain containing 1 |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of DEPDC1 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 2:248,684,508...248,717,951
Ensembl chr 2:248,684,523...248,717,951
|
|
G |
E2f8 |
E2F transcription factor 8 |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of E2F8 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
nobiletin results in increased expression of FOS mRNA |
CTD |
PMID:24964900 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
nobiletin inhibits the reaction [nonylphenol results in decreased expression of FSHB protein] |
CTD |
PMID:32815738 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
nobiletin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of GPT protein] |
CTD |
PMID:31777137 PMID:36850985 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases expression |
EXP |
nobiletin results in increased expression of GRIN1 mRNA |
CTD |
PMID:24964900 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
increases expression |
EXP |
nobiletin results in increased expression of GRIN2A mRNA |
CTD |
PMID:24964900 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
increases expression |
EXP |
nobiletin results in increased expression of GRIN2B mRNA |
CTD |
PMID:24964900 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
nobiletin inhibits the reaction [Arsenic results in decreased activity of GSR protein]; nobiletin inhibits the reaction [nonylphenol results in decreased activity of GSR protein] |
CTD |
PMID:32815738 PMID:36850985 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of H1-5 mRNA nobiletin results in decreased expression of H1F5 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
nobiletin inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 protein] |
CTD |
PMID:31777137 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
nobiletin inhibits the reaction [nonylphenol results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:32815738 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
nobiletin inhibits the reaction [nonylphenol results in decreased expression of HSD3B1 mRNA] |
CTD |
PMID:32815738 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; nobiletin inhibits the reaction [Acetaminophen results in increased expression of IL1B protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of IL1B protein] |
CTD |
PMID:31777137 PMID:32344236 PMID:36850985 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; nobiletin inhibits the reaction [Acetaminophen results in increased expression of IL6 protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of IL6 protein] |
CTD |
PMID:31777137 PMID:32344236 PMID:36850985 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of KIF11 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
nobiletin inhibits the reaction [nonylphenol results in decreased expression of LHB protein] |
CTD |
PMID:32815738 |
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
decreases expression |
ISO |
nobiletin results in decreased expression of MMP7 mRNA; nobiletin results in decreased expression of MMP7 protein |
CTD |
PMID:15725655 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein |
CTD |
PMID:32344236 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Muc5b |
mucin 5B, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
nobiletin inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein] |
CTD |
PMID:31777137 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
AGN 193109 inhibits the reaction [nobiletin results in decreased expression of and results in increased cleavage of PARP1 protein]; nobiletin results in decreased expression of and results in increased cleavage of PARP1 protein |
CTD |
PMID:33058988 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
nobiletin inhibits the reaction [Arsenic results in increased expression of PTGS2 protein] |
CTD |
PMID:36850985 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
AGN 193109 inhibits the reaction [nobiletin results in increased expression of RARB protein] nobiletin results in increased expression of RARB mRNA; nobiletin results in increased expression of RARB protein |
CTD |
PMID:33058988 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
nobiletin inhibits the reaction [SLC2A1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose] |
CTD |
PMID:36870413 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
ISO EXP |
nobiletin results in increased expression of SLC6A9 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP |
nobiletin inhibits the reaction [nonylphenol results in decreased expression of STAR mRNA] |
CTD |
PMID:32815738 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein |
CTD |
PMID:32344236 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tmem116 |
transmembrane protein 116 |
increases expression |
ISO EXP |
nobiletin results in increased expression of TMEM116 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr12:35,021,912...35,089,409
Ensembl chr12:35,041,572...35,089,430
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; nobiletin inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; nobiletin inhibits the reaction [Arsenic results in increased expression of TNF protein] |
CTD |
PMID:31777137 PMID:32344236 PMID:36850985 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO EXP |
nobiletin results in increased expression of TRIB3 mRNA |
CTD |
PMID:23321314 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO EXP |
nobiletin results in decreased expression of TXNIP mRNA; nobiletin results in decreased expression of TXNIP protein |
CTD |
PMID:23321314 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression decreases activity multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of ABCB1 mRNA 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of ABCB1 protein 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of and results in decreased activity of ABCB1 protein; diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of ABCB1 mRNA] |
CTD |
PMID:23470866 PMID:30790579 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases activity |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased activity of ABCG2 protein |
CTD |
PMID:32305507 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of BCL2 protein |
CTD |
PMID:19135124 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
decreases expression |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of CASP3 protein |
CTD |
PMID:19135124 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased cleavage of CASP8 protein |
CTD |
PMID:19135124 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of CASP9 protein |
CTD |
PMID:19135124 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CCL2 protein] |
CTD |
PMID:32464219 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in decreased expression of CDH5 protein] |
CTD |
PMID:32464219 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of CHEK2 protein modified form diacetyldiphenylurea bisguanylhydrazone inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:23470866 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Bleomycin results in increased expression of CSF2 mRNA] |
CTD |
PMID:32554301 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Bleomycin results in increased expression of CXCL1 mRNA] |
CTD |
PMID:32554301 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Bleomycin results in increased expression of CXCL1 mRNA] |
CTD |
PMID:32554301 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in increased expression of CYP1A1 protein |
CTD |
PMID:37515497 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
multiple interactions |
EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of ECE1 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of ECE1 protein] |
CTD |
PMID:26694894 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of EDN1 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of EDN1 mRNA]; [cyclo(Trp-Asp-Pro-Val-Leu) co-treated with BQ 788] inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one promotes the reaction [Lipopolysaccharides results in increased expression of EDN1 protein]] |
CTD |
PMID:26694894 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]] |
CTD |
PMID:29476730 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one results in decreased expression of FOS protein |
CTD |
PMID:22245252 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased activity of GPT protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased activity of GPT protein]] |
CTD |
PMID:29476730 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased activity of GPT protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of CXCL15 protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of IL6 protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of TNF protein]] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of and affects the localization of HIF1A protein]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in decreased expression of PPARA protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of FASN protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SCD protein]]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of SREBF1 protein]] |
CTD |
PMID:29476730 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in increased expression of HMGB1 protein] |
CTD |
PMID:32464219 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
[5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one co-treated with endotoxin, Escherichia coli] results in increased expression of IL10 protein |
CTD |
PMID:32464219 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Bleomycin results in increased expression of IL1A mRNA] |
CTD |
PMID:32554301 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA] 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [endotoxin, Escherichia coli results in increased expression of IL1B protein] |
CTD |
PMID:22101131 PMID:23236370 PMID:32464219 PMID:32554301 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Ethanol results in increased expression of IL6 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; HIF1A protein inhibits the reaction [5,7-dihydroxy-6-met | |